ImmuCell Corporation (ICCC) Earnings Call Transcripts
ImmuCell Corporation's Latest Earnings Call - Q1 FY2026
In the first quarter of fiscal year 2026, ImmuCell Corporation (ICCC:US) reported a significant milestone, achieving its first-ever $10 million revenue quarter, marking a 28.4% increase year-over-year. Net income also rose by 34% to $1.9 million, or $0.21 per share. Management highlighted a strategic focus on the calf scours market, particularly their First Defense product, which has gained market share and is expected to drive future growth. The company has maintained its guidance and is actively working on expanding production capacity to meet increasing demand.
Reported metrics
| Metric | Value |
|---|---|
| Revenue | $10.4 million (beat) |
| Net Income | $1.9 million (beat) |
| EPS | $0.21 (beat) |
| Gross Margin | 45% (beat) |
| Operating Expenses | $2.7 million (negative) |
| EBITDA | $2.6 million (beat) |
Guidance from management
Management maintained its guidance and expressed confidence in achieving further growth, particularly in the domestic market, while addressing international challenges.
What management said
Great quarter — congrats to the team on those results. Could you say a bit about your First Defense in bulk product, covering how seasonal it is, which market it aims at, and if it goes head-to-head with products already out there?
Sure, George, good to hear your voice; Tim speaking. What I'd say is that one difficulty with certain trends over recent years is the back order situation; a great deal depends on what inventory was there to offer buyers; and that, I think, produces some unusual patterns that might not make intuitive sense. So perhaps that explains what you're noticing. Broadly speaking, though, the direction is that a growing number...
What analysts pressed on
Analysts expressed concerns regarding the decline in international sales and the sustainability of domestic growth. Questions were raised about production capacity and how the company plans to manage future demand effectively.
Main topics on the call
- Record Revenue Achievement — ImmuCell reached a record $10 million in product sales for Q1 2026, a 28.4% increase from the prior year. CEO Oliver Te Boekhorst stated, "We achieved our first ever $10 million revenue quarter, which is an exciting mile...
- Gross Margin Improvement — Gross margins improved to 45% despite a 2.4% headwind from legacy costs. CFO Timothy Fiori noted, "We realized gross margin improvement in the first quarter compared to prior year," indicating effective cost management.
- Focus on First Defense Product — The strategic focus on First Defense has led to increased market share, with the product accounting for nearly 80% of category dollar expansion. Te Boekhorst emphasized, "We believe we are gaining share in this market, c...
- Challenges in International Sales — International sales declined by 30.2% to approximately $600,000, contrasting with strong domestic growth. CFO Fiori mentioned, "Domestic sales for the first quarter grew 35.7% compared to the first quarter of 2025," high...
Read the full ImmuCell Corporation transcript (Q1 FY2026) → Summary generated from the call transcript; every figure above is stated by management on the record.
About ImmuCell Corporation
ImmuCell Corporation (ICCC) is a publicly listed company in the Biotechnology industry, within the Health Care sector. It trades on NASDAQ and is based in US. EarningsCalls.dev maintains a full-text archive of its earnings call transcripts — 28 calls on record spanning February 19, 2020 to November 13, 2026. Every transcript is split into speaker-by-speaker segments with headline metrics. The latest calls are free to read; the full history is available through our REST API.
Earnings Call History
EarningsCalls.dev has 28 ImmuCell Corporation earnings call transcripts on record, spanning February 19, 2020 to November 13, 2026. Based on this history, ImmuCell Corporation reports quarterly. The most recent call on file is dated November 13, 2026. The full list is below — each row opens the transcript.
- Ticker
- ICCC
- Exchange
- NASDAQ
- Country
- US
- Sector
- Health Care
- Industry
- Biotechnology
- Calls on record
- 28
- First call
- February 19, 2020
- Most recent
- November 13, 2026
- Reporting cadence
- quarterly